medigraphic.com
ISSN 2007-932X (Electronic)
Órgano Oficial de Difusión de la Comisión Nacional de Arbitraje Médico

2022, Number 2

<< Back Next >>

Rev CONAMED 2022; 27 (2)

Genital bleeding secondary to hormone replacement therapy in a geriatric patient: case report of medical complaint

Ramírez MSN, Ensaldo CE, Peña LB, Méndez GS

Language: Spanish
References: 14
Page: 84-88
PDF size: 87.03 Kb.


ABSTRACT

Introduction: Hormone replacement therapy (HRT) is treatment employed to diminish climacteric symptoms. However, this treatment can also produce diverse adverse effects. Lack of communication between the physician and the patient about these secondary consequences can set up a perception of poor healthcare quality and result in issuing a complaint raised by the patient and their family. Objective: To describe a medical complaint case registered at the National Commission for Medical Arbitration (CONAMED) due to genital bleeding secondary to HRT. Case presentation: An 82-year-old woman, cancer survivor and with climacteric-related persistent symptomatology attended to a private clinic for receiving an HRT. This treatment produced genital bleeding and hormonal imbalance in the patient. In consequence, the patient made the decision to submit a complaint to CONAMED.


REFERENCES

  1. Palacios S, Stevenson JC, Schaudig K, Lukasiewicz M, Graziottin A. Hormone therapy for first-line management of menopausal symptoms: practical recommendations. Womens Health (Lond) [Internet]. 2019; 15: 1745506519864009. Available in: http://dx.doi.org/10.1177/1745506519864009

  2. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet [Internet]. 2015; 385 (9980): 1835-1842. Available in: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2814%2961687-1

  3. Langer RD, Hodis HN, Lobo RA, Allison MA. Hormone replacement therapy - where are we now? Climacteric [Internet]. 2021; 24 (1): 3-10. Available in: https://doi.org/10.1080/13697137.2020.1851183

  4. García-Vera EM, Robles-Rodríguez A, Villegas-Bernabé ML, Figueroa-García J, Mota-Cumpean AE. La comunicación médico paciente ¿reto para el paciente geriátrico o para el médico familiar? Aten Fam. 2016; 23 (2): 63-66.

  5. Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors - review of the literature. Pathol Oncol Res [Internet]. 2020; 26 (1): 63-78. Available in: http://dx.doi.org/10.1007/s12253-018-00569-x

  6. Duarte Jeremías M, Vargas Chaves S. Tratamiento local del síndrome genitourinario en la menopausia. Rev Med Sinerg. [Internet]. 2020; 5 (9): e570. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/570

  7. Ochoa Moreno JA. ¿Qué son los derechos de las y los pacientes y como incorporarlos a la práctica médica? Boletín CONAMED OPS [Internet]. 2016. Disponible en: http://www.conamed.gob.mx/gobmx/boletin/pdf/boletin8/derechos_pacientes.pdf

  8. Hashim MJ. Patient-centered communication: basic skills. Am Fam Physician. 2017; 95 (1): 29-34.

  9. Belasen A, Belasen AT. Doctor-patient communication: a review and a rationale for using an assessment framework. J Health Organ Manag [Internet]. 2018; 32 (7): 891-907. Available in: http://dx.doi.org/10.1108/JHOM-10-2017-0262

  10. NORMA Oficial Mexicana NOM-220-SSA1-2012, Instalación y operación de la farmacovigilancia [Internet]. 2012 [Citado 20 de febrero de 2022]. Disponible en: http://dof.gob.mx/nota_detalle.php?codigo=5490830&fecha=19/07/2017#:~:text=La%20Farmacovigilancia%20se%20considera%20como,y%20vacunas%20en%20seres%20humanos

  11. NORMA Oficial Mexicana NOM-004-SSA3-2012, Del expediente clínico [Internet]. 2012 [Citado 20 de febrero de 2022]. Disponible en: http://dof.gob.mx/nota_detalle_popup.php?codigo=5272787

  12. Instituto Mexicano del Seguro Social. Guía de Práctica Clínica, Atención de los padecimientos ginecológicos más frecuentes en la postmenopausia [Internet]. [Consultado 25 de febrero de 2022] Disponible en: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/568GRR.pdf

  13. Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother [Internet]. 2019; 20 (7): 821-835. Available in: http://dx.doi.org/10.1080/14656566.2019.1574752

  14. Hipolito Rodrigues MA, Gompel A. Micronized progesterone, progestins, and menopause hormone therapy. Women Health [Internet]. 2021; 61 (1): 3-14. Available in: http://dx.doi.org/10.1080/03630242.2020.1824956




2020     |     www.medigraphic.com